Scarica l'app Stockscreener
1.28
0.00%
0.00
Dopo l'orario di chiusura:
1.27
-0.01
-0.78%
Inmune Bio Inc Borsa (INMB) Ultime notizie
INMB Q4 2025 Earnings: EPS Surprise of 24.6% Highlights Operational ProgressNon-GAAP Earnings - newsline.com
INMB Q4 2025 Earnings: EPS Beat Surprises Street as Clinical Pipeline AdvancesTax Rate Impact - newsline.com
INmune Bio reports positive Phase 2 MRI results - TipRanks
New MRI biomarker backs INmune Bio (NASDAQ: INMB) Alzheimer’s drug - Stock Titan
INMB: INmune Bio Reports Promising MRI Findings from Alzheimer's Trial - GuruFocus
INmune Bio Reports Statistically Significant Treatment Effect On Advanced White Matter MRI Biomarker In Phase 2 MINDFuL Alzheimer's Trial - marketscreener.com
INmune Bio reports positive MRI results from Alzheimer’s trial - Investing.com
INmune Bio Reports Statistically Significant Treatment Effect On Advanced White Matter MRI Biomarker In Phase 2 Mindful Alzheimer's Trial - TradingView
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial - The Manila Times
Brain scans in early Alzheimer’s trial show drug affecting white matter - Stock Titan
INMB Q4 2025 Earnings: Narrowed Loss Per Share Exceeds Expectations Amidst Pipeline ProgressEarnings Revision Upgrade - newsline.com
INmune Bio (INMB) Q4 2025 Earnings Transcript - The Globe and Mail
INmune Bio Inc. (INMB) Navigates Near Support Levels Amid Modest DeclineValue Stock Ideas - newsline.com
INmune Bio (INMB) Holds Near Support Amid Modest Decline – Key Levels in FocusAAII Bearish - newsline.com
Inmune Bio Inc stock (US45764T1060): Short interest rose in May - AD HOC NEWS
INMB Q4 2025 Earnings: EPS Beat Surprises as Clinical-Stage Biotech Advances PipelineConsensus Miss Rate - The Legal Advocate
INmune Bio Inc. (INMB) Slips Further as Stock Tests Key Support at $1.35BPI Reversal - The Legal Advocate
INmune Bio Inc. (INMB) Holds Near Support as Biotech Stock Edges HigherTake Profit Levels - newsline.com
INMB Q4 2025 Earnings: Narrower Loss Beats Estimates, Pipeline Progress HighlightedWeak Earnings Momentum - The Legal Advocate
INMB Q4 2025 Earnings: EPS Surpasses Estimates as Loss NarrowsEarnings Stability Report - thelegaladvocate.com
INMB Q4 2025 Earnings: Narrowing Losses Amid Clinical Pipeline ProgressInterim Report - newsline.com
Inmune Bio Inc stock (US45764T1060): eyes on upcoming 2025 results and Alzheimer’s pipeline - AD HOC NEWS
INMB Stock Price, Quote & Chart | INMUNE BIO INC (NASDAQ:INMB) - ChartMill
INmune Bio (INMB) Crushes Q4 2025 Estimates — EPS $-0.20 Tops ViewsBanking Earnings Report - The Legal Advocate
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro Platform - marketscreener.com
Inmune Bio stock (US45764T1060): Year-end 2025 results and update in focus - AD HOC NEWS
INmune Bio publishes Alzheimer’s trial results in journal - Investing.com UK
INMB Shows Promising Alzheimer's Results in MINDFuL Trial - GuruFocus
INmune Bio: Interview With Co-Founder & CEO David Moss About The Immunotherapies Company - Pulse 2.0
INmune Bio publishes Alzheimer’s trial results in journal By Investing.com - Investing.com South Africa
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform - The Manila Times
Alzheimer’s drug XPro shows directionally consistent benefits, no ARIA - Stock Titan
INmune Bio Receives FDA Fast Track for XPro - TipRanks
INMB Secures Fast Track Designation for Alzheimer's Treatment - GuruFocus
INmune Bio (NASDAQ: INMB) wins FDA Fast Track status for XPro in early Alzheimer’s disease - Stock Titan
INmune Bio receives FDA fast track status for Alzheimer’s drug - Investing.com UK
INmune Bio (INMB) Stock: Up +14.73%, Key Resistance at $1.76 2026-05-14Expert Entry Points - newser.com
INmune Bio's XPro1595 gets FDA Fast Track for early Alzheimer's treatment - Pluang
INmune Bio stock surges on FDA Fast Track for Alzheimer’s drug By Investing.com - Investing.com South Africa
INmune Bio stock surges on FDA Fast Track for Alzheimer’s drug - Investing.com Australia
INmune Bio receives FDA fast track designation for XPro1595 in early Alzheimer's disease - marketscreener.com
INmune Bio receives FDA fast track status for Alzheimer’s drug By Investing.com - Investing.com Australia
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease - The Manila Times
FDA Fast Tracks brain-inflammation drug for early Alzheimer’s - Stock Titan
INmune Bio (INMB) Q1 2026 Earnings Transcript - AOL.com
INmune Bio joins 26 companies to form American Biotech Innovation Alliance for US biotech leadership - Pluang
TradingKey - TradingKey
INmune Bio, Inc. (NASDAQ:INMB) Q1 2026 Earnings Call Transcript - Insider Monkey
INMB: INmune BioInteractive Chart - Zacks Investment Research
Expanding partnership aims to advance stem cell therapy to treat RDEB - Epidermolysis Bullosa News
Q1 2026 INmune Bio Inc Earnings Call Transcript - GuruFocus
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):